Goldman Sachs initiated coverage of HealthEquity (HQY) with a Neutral rating and $108 price target The firm says its thesis on HealthEquity is balanced by a constructive view on the company’s forward earnings outlook and a clear path to achieving long-term earnings targets with what it sees as a balanced risk/reward based on valuation.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.